HIMS nabbed a pre-earnings record high
Weight-loss drugs have been popular over the past couple of years, and Hims & Hers Health Inc (NYSE:HIMS), Novo Nordisk A/S (NYSE:NVO), and Viking Therapeutics Inc (NASDAQ:VKTX) are among the most recognized names in the industry. Below, we check in with these pharma giants to see how they are faring.
HIMS Nabs Fresh Record
HIMS is up 17.5% to trade at $54.50 at last glance, and earlier nabbed a record peak of $56.71 on its way to its best single-day percentage gain since November, while sporting a 438.7% year-over-year lead. The company aired an ad during this year's Super Bowl, and is gearing up to post fourth-quarter results after the close on Monday, Feb. 24. It's worth noting the shares have a negative history of post-earnings reactions, however, finishing five of the last eight next-day sessions lower.
NVO Approaches 52-Week Lows
NVO was last seen down 3.1% to trade at $79.29, despite news that its Ozempic drug efficacy in treating some marker of alcohol disorders, according to a new study. Shares have shed 42.3% in the last nine months, and are today pacing for a fifth-straight daily loss as they approach their Jan. 17, 52-week low of $78.17. What's more, the security has struggled with overhead pressure at the $90 level since late December.
VKTX Brushes Off Bullish Coverage
VKTX is down 2.1% to trade at $28.70 at last check, on track for its fifth loss over the last six sessions after hitting its lowest level in 12 months earlier. The equity is brushing off new coverage from Scotiabank, which doled out an "outperform" rating and set its price target at $102. Shares carry a 58.3% nine-month deficit, and shed 28.5% just this year.